XML 81 R36.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAX EXPENSE (Tables)
12 Months Ended
Dec. 31, 2022
INCOME TAX EXPENSE  
Schedule of components of income tax expense

For the years ended December 31,

    

2020

    

2021

    

2022

US$

US$

US$

Current:

U.S.

Federal

 

 

1,290,009

 

672,064

State and local

 

 

367,441

 

(168,846)

Total current

 

 

1,657,450

 

503,218

Deferred:

 

  

 

  

 

  

U.S.

Federal

 

 

96,804

 

(96,804)

State and local

 

 

(52,641)

 

52,641

Total deferred

 

 

44,163

 

(44,163)

Income tax expense

 

 

1,701,613

 

459,055

Schedule of reconciliation between the income tax expense and the actual provision

For the years ended December 31,

 

    

2020

    

2021

    

2022

 

US$

US$

US$

 

Loss before income tax

 

(42,397,279)

 

(71,476,322)

 

(79,512,792)

PRC statutory income tax rate

25

%

25

%

25

%

Income tax credit computed at PRC statutory income tax rate

(10,599,320)

 

(17,869,081)

 

(19,878,198)

Impact of PRC preferential income tax rate as qualified TASE

4,239,728

7,147,633

7,951,279

Difference in income tax rates of overseas entities

5,286,487

10,549,985

10,560,029

Research and development super-deduction(a)

(718,979)

 

(569,016)

 

(1,724,740)

Research and development tax credits

(569,575)

Non-deductible expenses

1,238

 

1,054

 

3,695

Foreign derived intangible income deduction

(487,183)

Changes in valuation allowance

1,790,846

 

2,277,418

 

4,517,358

State tax

291,500

76,127

Others

(127,880)

10,263

Income tax expense

1,701,613

459,055

Note (a): Due to the impacts of research and development super-deduction, the Group’s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the years ended December 31, 2020, 2021, and 2022.

Schedule of tax effects of temporary differences that give rise to the deferred tax balances

As of December 31,

    

2021

    

2022

US$

US$

Deferred tax assets:

  

Net operating loss carry forward

4,949,000

 

8,217,976

Tax credit carry forward

391,843

Capitalized research and development expenses

756,197

Capitalized inventory

95,589

94,954

Unrealized foreign exchange gain/losses

39,166

116,238

Accrued expenses

29,702

Amortization of right-of-use assets and interest of lease liabilities

546

Depreciation and amortization of property, equipment and software

79

 

Gross deferred tax assets

5,083,834

 

9,607,456

Less: valuation allowance

(5,007,139)

 

(9,524,497)

Deferred tax assets

76,695

 

82,959

Deferred tax liabilities:

    

    

Depreciation and amortization of property, equipment and software

 

(120,858)

 

(82,959)

Deferred tax liabilities

 

(120,858)

 

(82,959)

Total deferred tax liabilities, net

 

(44,163)

 

Schedule of movement of the valuation allowance

    

2021

    

2022

US$

US$

Balance as of January 1

 

2,729,721

 

5,007,139

Addition

 

2,277,418

 

4,517,358

Balance as of December 31

 

5,007,139

 

9,524,497